-
公开(公告)号:US20110190293A1
公开(公告)日:2011-08-04
申请号:US13085048
申请日:2011-04-12
IPC分类号: A61K31/5377 , C07D239/91 , A61K31/517 , A61P35/00 , C07D413/04 , C07D413/06
CPC分类号: C07D401/06 , C07D239/90
摘要: Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译: 喹唑啉酮化合物,其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种喹唑啉酮化合物的组合物,单独或与至少一种另外的治疗剂组合。 单独使用喹唑啉酮化合物或与至少一种其它治疗剂组合使用的方法可用于预防或治疗增殖性疾病。
-
公开(公告)号:US07939539B2
公开(公告)日:2011-05-10
申请号:US10996814
申请日:2004-11-24
IPC分类号: A61K31/517 , C07D239/88
CPC分类号: C07D401/06 , C07D239/90
摘要: Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译: 喹唑啉酮化合物,其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种喹唑啉酮化合物的组合物,单独或与至少一种另外的治疗剂组合。 单独使用喹唑啉酮化合物或与至少一种其它治疗剂组合使用的方法可用于预防或治疗增殖性疾病。
-
3.
公开(公告)号:US07326711B2
公开(公告)日:2008-02-05
申请号:US10870707
申请日:2004-06-17
申请人: Weibo Wang , Ryan N. Constantine , Liana Marie Lagniton , Sabina Pecchi , Matthew T. Burger , Manoj C. Desai
发明人: Weibo Wang , Ryan N. Constantine , Liana Marie Lagniton , Sabina Pecchi , Matthew T. Burger , Manoj C. Desai
IPC分类号: A61K31/519 , A61K35/00 , C07D487/04
CPC分类号: C07D471/04
摘要: Pyridin[1,2-a]pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.
摘要翻译: 吡啶并[1,2-a]嘧啶基化合物,其药学上可接受的盐和前药; 包括药学上可接受的载体和一种或多种吡啶并[1,2-a]嘧啶基化合物的组合物,单独或与至少一种另外的治疗剂组合。 单独或与至少一种其它治疗剂组合使用吡啶并[1,2-a]嘧啶基化合物在预防或治疗增殖性疾病中的方法。
-
公开(公告)号:US08486942B2
公开(公告)日:2013-07-16
申请号:US13301642
申请日:2011-11-21
申请人: Manoj C. Desai , Allen Y. Hong , Hon C. Hui , Hongtao Liu , Randall W. Vivian , Lianhong Xu
发明人: Manoj C. Desai , Allen Y. Hong , Hon C. Hui , Hongtao Liu , Randall W. Vivian , Lianhong Xu
IPC分类号: A61K31/5355
CPC分类号: G01N33/94 , A61K9/0053 , A61K9/08 , A61K31/4178 , A61K31/426 , A61K31/427 , A61K31/496 , A61K31/5377 , A61K45/06 , C07B2200/05 , C07D277/28 , C07D277/30 , C07D417/14 , G01N33/58 , A61K2300/00
摘要: The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
摘要翻译: 本申请提供式IV化合物或其药学上可接受的盐,溶剂合物和/或酯,含有这些化合物的组合物,包括施用这些化合物的治疗方法和治疗方法,包括给予这些化合物 与至少一种另外的治疗剂。
-
公开(公告)号:US08383655B2
公开(公告)日:2013-02-26
申请号:US13103970
申请日:2011-05-09
申请人: Manoj C. Desai , Allen Yu Hong , Hongtao Liu , Randall W. Vivian , Lianhong Xu
发明人: Manoj C. Desai , Allen Yu Hong , Hongtao Liu , Randall W. Vivian , Lianhong Xu
IPC分类号: A61K31/426
CPC分类号: A61K31/427 , A61K31/426 , A61K31/4402 , A61K31/4535 , A61K31/47 , A61K31/496 , A61K31/5377 , A61K38/005 , A61K38/05 , A61K45/00 , A61K45/06 , C07C209/78 , C07C227/16 , C07C227/18 , C07C315/04 , C07D277/24 , C07D277/28 , C07D277/30 , C07D417/14 , C07K5/06 , C07K5/06026 , C07K5/06034 , C07K5/06052 , A61K2300/00
摘要: The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
-
公开(公告)号:US08338593B2
公开(公告)日:2012-12-25
申请号:US12303214
申请日:2007-07-06
申请人: Lee S. Chong , Manoj C. Desai , Brian Gallagher , Michael Graupe , Randall L. Halcomb , Hong Yang , Jennifer R. Zhang
发明人: Lee S. Chong , Manoj C. Desai , Brian Gallagher , Michael Graupe , Randall L. Halcomb , Hong Yang , Jennifer R. Zhang
IPC分类号: C07F9/6561 , C07D473/16 , A61K31/675 , A61P31/20 , C07D473/40
CPC分类号: C07F9/65616
摘要: The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent.
摘要翻译: 本申请提供式(I)或(II)的化合物或其药学上可接受的盐,溶剂合物和/或酯,含有这些化合物的组合物,包括施用这些化合物的治疗方法和治疗方法, 包括给予这些化合物与至少一种另外的活性剂。
-
公开(公告)号:US20090291922A1
公开(公告)日:2009-11-26
申请号:US12436004
申请日:2009-05-05
申请人: Xiaoqin Cheng , Gary P. Cook , Manoj C. Desai , Edward Doerffler , Gong-Xin He , Choung U. Kim , William A. Lee , John C. Rohloff , Jianying Wang , Zheng-Yu Yang
发明人: Xiaoqin Cheng , Gary P. Cook , Manoj C. Desai , Edward Doerffler , Gong-Xin He , Choung U. Kim , William A. Lee , John C. Rohloff , Jianying Wang , Zheng-Yu Yang
IPC分类号: A61K31/675 , C07D473/16 , A61K31/52 , C07F9/02
CPC分类号: C07F9/65616 , Y02P20/55
摘要: Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y1A and Y1B are independently Y1; RX1 and RX2 are independently RX; Y1 is ═O, —O(RX), ═S, —N(RX), —N(O)(RX), —N(ORX), —N(O)(ORX), or —N(N(RX)(RX)); RX is independently R1, R2, R4, W3, or a protecting group; R1 is independently —H or alkyl of 1 to 18 carbon atoms; R2 is independently R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups; R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d; R3a is —H, —F, —Cl, —Br, —I, —CF3, —CN, N3, —NO2, or —OR4; R3b is ═O, —O(R4), ═S, —N(R4), —N(O)(R4), —N(OR4), —N(O)(OR4), or —N(N(R4)(R4)); R3c is —R4, —N(R4)(R4), —SR4, —S(O)R4, —S(O)2R4, —S(O)(OR4), —S(O)2(OR4), —OC(R3b)R4, —OC(R3b)OR4, —OC(R3b)(N(R4)(R4)), —SC(R3b)R4, —SC(R3b)OR4, —SC(R3b)(N(R4)(R4)), —N(R4)C(R3b)R4, —N(R4)C(R3b)OR4, —N(R4)C(R3b) (N(R4)(R4)), W3 or —R5W3; R3d is —C(R3b)R4, —C(R3b)OR4, —C(R3b)W3, —C(R3b)OW3 or —C(R3b)(N(R4)(R4)); R4 is —H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W3 is W4 or W5; W4 is R6, —C(R3b)R6, —C(R3b)W5, —SOM2R6, or —SOM2W5, wherein R6 is R4 wherein each R4 is substituted with 0 to 3 R3 groups; W5 is carbocycle or heterocycle wherein W5 is independently substituted with 0 to 3 R2 groups; and M2 is 0, 1 or 2; and pharmaceutically acceptable salts thereof.
-
公开(公告)号:US20090181902A1
公开(公告)日:2009-07-16
申请号:US12217496
申请日:2008-07-03
申请人: Manoj C. Desai , Hon C. Hui , Hongtao Liu , Jianyu Sun , Lianhong Xu
发明人: Manoj C. Desai , Hon C. Hui , Hongtao Liu , Jianyu Sun , Lianhong Xu
IPC分类号: A61K38/05 , C07D417/12 , A61K31/427 , C07D417/14 , A61K31/5377 , A61K31/496 , A61P31/12
CPC分类号: C07D277/28 , C07D417/14
摘要: The present application provides for a compound of Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
摘要翻译: 本申请提供式IV化合物或其药学上可接受的盐,溶剂合物和/或酯,含有这些化合物的组合物,包括施用这些化合物的治疗方法和治疗方法,包括给予这些化合物 与至少一种另外的治疗剂。
-
公开(公告)号:USRE39708E1
公开(公告)日:2007-06-26
申请号:US10757347
申请日:2004-01-13
申请人: Verena D. Huebner , Xiaodong Lin , Ian James , Liya Chen , Manoj C. Desai , Beata Krywult , Rajinder Singh , Liang Wang
发明人: Verena D. Huebner , Xiaodong Lin , Ian James , Liya Chen , Manoj C. Desai , Beata Krywult , Rajinder Singh , Liang Wang
IPC分类号: A61K31/415 , A61P19/10 , C07D231/12
CPC分类号: C07D401/04 , C07D231/12 , C07D231/54 , C07D403/04 , C07D409/04
摘要: Estrogen receptor-modulating pyrazole compounds are described in addition to methods and compositions for treating or preventing estrogen receptor-mediated disorders. The compounds described have been found to have unexpected and surprising activity in modulating estrogen receptor activity. Thus, the compounds of the present invention have utility in preventing or treating estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease.
摘要翻译: 除了用于治疗或预防雌激素受体介导的病症的方法和组合物之外还描述了雌激素受体调节性吡唑化合物。 已经发现所描述的化合物在调节雌激素受体活性方面具有意想不到的和惊人的活性。 因此,本发明的化合物可用于预防或治疗雌激素受体介导的疾病如骨质疏松症,乳腺癌和子宫内膜癌,动脉粥样硬化和阿尔茨海默氏病。
-
公开(公告)号:US5688806A
公开(公告)日:1997-11-18
申请号:US513798
申请日:1995-10-12
IPC分类号: A61K31/435 , A61P25/00 , A61P25/04 , A61P25/30 , A61P29/00 , C07D211/76 , C07D471/10 , A61K31/445
CPC分类号: C07D471/10 , C07D211/76
摘要: The present invention relates to novel spirocyclic piperidine derivatives and related compounds and, specifically, to compounds of the formula ##STR1## wherein X, Z, Y, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and m are as defined in the specification, and to intermediates used in the synthesis of such compounds. The novel compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
摘要翻译: PCT No.PCT / US93 / 11793 Sec。 371 1995年10月12日第 102(e)日期1995年10月12日PCT 1993年12月10日PCT PCT。 第WO94 / 20500号公报 日期1994年9月15日本发明涉及新型的螺环哌啶衍生物和相关化合物,具体地说,涉及式m化合物如本说明书中所定义,以及用于合成这些化合物的中间体。 式I的新型化合物可用于治疗炎性和中枢神经系统疾病以及其它疾病。
-
-
-
-
-
-
-
-
-